A Personalized Cancer Medicine Resource for Oncology Providers

In this article, we discuss a new app to help oncology practitioners make genetically informed treatment decisions for their cancer patients.

Recent Content

For those patients diagnosed with localized prostate cancer, the risk of recurrence is approximately 30%--even years after initial treatment.

A 34-year-old man presents with symptoms of appendicitis which required having his appendix removed. What is your diagnosis?

Ephrin type-A receptor 2 (EpHA2), a protein that in humans is encoded by the EPHA2 gene, is a promising target that may help identify patients who are at risk for developing aggressive colorectal cancer (CRC).

Neoadjuvant therapy in breast cancer is a hot topic these days. Giving drugs in the neoadjuvant setting has several advantages:

A 27-year-old man is found to have an anterior mediastinal mass. A biopsy of the mass is performed. What is your diagnosis?

The concept of individualized or personalized medicine in oncology has evolved from the use of imatinib (Gleevec) to target the breakpoint cluster region-Abelson protein (BCR-ABL) in chronic myelogenous leukemia, to next generation sequencing panels able to provide more complete genetic analysis of a given tumor or malignant cell.

My task: teach the residents about oncology. I attempted to impart my newly found knowledge about hematology and oncology to this group of wonderful (even more neophyte than myself), physicians.

By clicking Accept, you agree to become a member of the UBM Medica Community.